

			Study Phase	Rater	(Current) dosage	IV administration	Anti-CCP	BMI	CDAI	CRP	Cototherapy	DAS28-ESR	Disease duration	ESR	Evaluator VAS-Activity (mm)	HAQ	Patient VAS-Activity (mm)	Patient VAS-Pain (mm)	SDAI	SJC	Smoker Status	TJC	bDMARD
P1	1	R1																					
P1	1	R2																					
P1	1	R3																					
P1	1	R4																					
P1	1	R5																					
P2	1	R1																					
P2	1	R2																					
P2	1	R3																					
P2	1	R4																					
P2	1	R5																					
P3	1	R1																					
P3	1	R2																					
P3	1	R3																					
P3	1	R4																					
P3	1	R5																					
P4	1	R1																					
P4	1	R2																					
P4	1	R3																					
P4	1	R4																					
P4	1	R5																					
P5	1	R1																					
P5	1	R2																					
P5	1	R3																					
P5	1	R4																					
P5	1	R5																					
P6	1	R1																					
P6	1	R2																					
P6	1	R3																					
P6	1	R4																					
P6	1	R5																					
P7	1	R1																					
P7	1	R2																					
P7	1	R3																					
P7	1	R4																					
P7	1	R5																					
P8	1	R1																					
P8	1	R2																					
P8	1	R3																					
P8	1	R4																					
P8	1	R5																					
P9	1	R1																					
P9	1	R2																					
P9	1	R3																					
P9	1	R4																					
P9	1	R5																					
P10	1	R1																					
P10	1	R2																					
P10	1	R3																					
P10	1	R4																					
P10	1	R5																					

Figure S1: Feature importance rating according to individual patient and physician (T1).
 IV, intravenous; Anti-CCP, anti-citrullinated protein antibody; BMI, body mass index; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein, DAS28-ESR, Disease Activity Index 28-erythrocyte sedimentation rate; VAS, visual analogue scale; HAQ, Health Assessment Questionnaire; SDAI, Simple Disease Activity Index; SJC, swollen joint count; TJC, tender joint count; bDMARD, biologic Disease-Modifying Antirheumatic Drugs. Red represents that the parameter was rated as important, white as not important.

[illegible]

Figure S2: Feature importance rating according to individual patient and physician (T2).

IV, intravenous; Anti-CCP, anti-citrullinated protein antibody; BMI, body mass index; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS28-ESR, Disease Activity Index 28-erythrocyte sedimentation rate; VAS, visual analogue scale; HAQ, Health Assessment Questionnaire; SDAI, Simple Disease Activity Index; SJC, swollen joint count; TJC, tender joint count; bDMARD, biologic Disease-Modifying Antirheumatic Drugs. Red represents that the parameter was rated as important, white as not important.